the classical drugs used to decrease prolactin production and release from the pituitary, do not affect production of prolactin in nonpituitary tissues Prolactin-receptor antagonists are ...

Spironolactone is a nonselective aldosterone antagonist, and eplerenone is selective to the aldosterone receptor. Although numerous clinical trials have evaluated the efficacy of each drug ...

The Food and Drug Administration (FDA ... ST316, an investigational β-catenin and BCL9 interaction peptide antagonist, inhibits the Wnt enhanceosome protein complex formulation that leads ...

Ariceum Therapeutics GmbH’s radiopharmaceutical 225Ac-SSO110 ([225Ac]satoreotide tetraxetran) has been awarded orphan drug designation by the FDA for the treatment of small-cell lung cancer (SCLC).